Baird served as co-manager on the offering
AboutMyovant Sciences, Ltd. (“Myovant”) (NYSE:MYOV) recently completed a follow-on offering of 3,333,334 shares of common stock at a price to the public of $22.50 per share raising gross proceeds of $75.0 million. Myovant intends to use the net proceeds from the offering primarily to fund its clinical development programs, preparations for the potential commercial launch of relugolix, as well as for working capital and other general corporate purposes.
Myovant is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of women's health and endocrine diseases. Myovant's goal is to be the leading global biopharmaceutical company focused on treating women's health and endocrine diseases in areas of high unmet medical need. Myovant’s principal office is located in London, the United Kingdom.
CONTACT US TO LEARN MORE
- July 2018
- Myovant Sciences, Ltd.
- Target Location